Phase 3 Cardiomyopathy Trial, Recruiting (NCT06846086)

Phase 3 Cardiomyopathy Trial, Recruiting NCT06846086 Sponsor: Tanta University Condition: Cardiomyopathy

Printed from Voxsanity (voxsanity.com.au) — NCT06846086 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Cardiomyopathy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are 18 years old or older and have been diagnosed with a heart muscle disease (cardiomyopathy), confirmed by tests such as an ultrasound of the heart or other imaging.
Your condition is stable and you are already taking standard medications for cardiomyopathy, such as ACE inhibitors or beta-blockers.
You are able to understand and agree to participate by signing a consent form.

Who may not be able to join:

You have been hospitalized for a worsening of your heart muscle disease in the last 3 months.
You have serious kidney or liver problems.
You are currently taking other experimental drugs or antioxidant supplements.
You are pregnant or planning to become pregnant in the next 6 months.
You have had a known allergic reaction to melatonin in the past.
You have an irregular heart rhythm condition called atrial fibrillation, or another significant heart rhythm problem, at the time of joining the trial.
You are currently taking part in another research study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +201124425525

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06846086

Sponsor: Tanta University

Phase: Phase 3

Status: Recruiting

Condition: Cardiomyopathy

Trial contact: +201124425525

More information: https://clinicaltrials.gov/study/NCT06846086

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are 18 years old or older and have been diagnosed with a heart muscle disease (cardiomyopathy), confirmed by tests such as an ultrasound of the heart or other imaging.
Your condition is stable and you are already taking standard medications for cardiomyopathy, such as ACE inhibitors or beta-blockers.
You are able to understand and agree to participate by signing a consent form.

Who may not be able to join:

You have been hospitalized for a worsening of your heart muscle disease in the last 3 months.
You have serious kidney or liver problems.
You are currently taking other experimental drugs or antioxidant supplements.
You are pregnant or planning to become pregnant in the next 6 months.
You have had a known allergic reaction to melatonin in the past.
You have an irregular heart rhythm condition called atrial fibrillation, or another significant heart rhythm problem, at the time of joining the trial.
You are currently taking part in another research study.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 3

Sponsor

Tanta University

Registry

ClinicalTrials.gov

Start date

20 February 2025

Est. completion

1 January 2026

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

Blood Pressure Measurement; Heart Rate (HR) Measurement; Echocardiographic Parameters; Echocardiographic Parameters; Serum Concentration of NT Pro- BNP

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov